Allergen, Mites, Lepidoglyphus destructor

Also known as: LEPIDOGLY

Clinical Use

Use

This test measures allergen-specific IgE levels to Lepidoglyphus destructor, providing insight into potential allergic reactions. The quantitative ImmunoCAP fluorescent enzyme immunoassay delivers results in kilounits per liter (kU/L), aiding in the diagnosis and management of allergic diseases where dust mite sensitivity is suspected. The results must be interpreted in conjunction with clinical history and other diagnostic tests, such as skin testing, to understand their significance and potential implications for patient care. A direct correlation between IgE concentrations and clinical severity or in vivo reactivity should not be assumed.

Special Instructions

Not provided.

Limitations

The test may not entirely predict clinical reactivity, and a negative result does not exclude the possibility of an allergy or anaphylactic response. The presence of allergen-specific IgE indicates sensitization but does not necessarily correlate with the severity of clinical symptoms. Results categorized in the 0.10-0.34 kU/L range are especially challenging as their clinical relevance remains undetermined without specialist interpretation. Variations in IgE concentrations do not uniformly correlate with specific clinical reactions or skin test outcomes, emphasizing the need for integration with clinical history.

Test Details

FDA Approved